Key result
Multigene PGx testing projects ~18 actionable non-antiplatelet medication interventions per 100 PCI patients.
Why the study?
CYP2C19 genotyping guides antiplatelet therapy after PCI, but the potential impact of CYP2C19 and multigene pharmacogenomics testing on medications beyond antiplatelet therapy in this population was unknown.
Does multigene pharmacogenomic testing impact medication prescribing beyond antiplatelet therapy in PCI patients?
Observational
Does multigene pharmacogenomic testing impact medication prescribing beyond antiplatelet therapy in PCI patients?
Multigene pharmacogenomic testing in PCI patients has the potential to optimize the prescribing of non-antiplatelet medications, such as proton pump inhibitors, antidepressants, and opioids.
Projected yield may extend pharmacogenomic utility beyond antiplatelets in PCI; leaves open impact on prescribing and outcomes.
Aim: CYP2C19 genotyping is used to guide antiplatelet therapy after percutaneous coronary intervention (PCI). This study evaluated the potential impact of CYP2C19 and multigene pharmacogenomics (PGx) testing on medications beyond antiplatelet therapy in a real-world cohort of PCI patients that underwent CYP2C19 testing. Methodology & results: Multiple medications with actionable PGx recommendations, including proton pump inhibitors, antidepressants and opioids, were commonly prescribed. Approximately 50% received a CYP2C19 metabolized medication beyond clopidogrel and 7% met criteria for a CYP2C19 genotype-guided intervention. A simulation analysis projected that 17.5 PGx-guided medication interventions per 100 PCI patients could have been made if multigene PGx results were available. Conclusion: This suggests that CYP2C19 and multigene PGx results could be used to optimize medication prescribing beyond antiplatelet therapy in PCI patients.
No takes yet. Share an insight, caveat, or question.
Black et al. (2020) conducted an observational in Percutaneous Coronary Intervention (PCI). CYP2C19 and multigene pharmacogenomics (PGx) testing was evaluated on Projected PGx-guided medication interventions per 100 PCI patients. Multigene pharmacogenomic testing in PCI patients was projected to yield 17.5 actionable medication interventions per 100 patients for medications beyond antiplatelet therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: